Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

NCT03219333 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT03219333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03219333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
October 8, 2017
Completion date
July 28, 2023
Enrollment
219 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, transitional cell, renal pelvis neoplasms, ureteral neoplasms, urethral neoplasms, urinary bladder neoplasms, urologic neoplasms, urothelial cancer